Regeneron and Fujifilm Diosynth Biotechnologies Announce Groundbreaking $3B Partnership

In a significant move to bolster the production of commercial biologic medicines in the United States, Regeneron Pharmaceuticals Inc. has entered into a monumental agreement with Fujifilm Diosynth Biotechnologies. This collaboration, centered at Fujifilm's campus in North Carolina, represents a total investment surpassing $3 billion over a ten-year period, including technology transfer efforts.

Daniel Van Plew, Regeneron's Executive Vice President, emphasized the strategic importance of this partnership, stating, "Our alliance with Fujifilm is a testament to our shared commitment to excellence and innovation in biologics manufacturing. We are eagerly advancing our collaborative efforts at the Holly Springs facility to meet the growing demand for our medicines."

Additionally, Regeneron highlighted its broader investment strategy, with over $7 billion earmarked for expanding production and infrastructure across New York and North Carolina, underscoring its dedication to strengthening the US biotech sector.